Enovix (NASDAQ:ENVX – Free Report) had its target price boosted by Canaccord Genuity Group from $17.00 to $20.00 in a report published on Thursday, Benzinga reports. They currently have a buy rating on the stock.
Other equities analysts have also issued reports about the stock. William Blair reiterated an outperform rating on shares of Enovix in a report on Thursday, May 2nd. Benchmark initiated coverage on shares of Enovix in a report on Monday, July 22nd. They issued a buy rating and a $25.00 target price on the stock. JPMorgan Chase & Co. decreased their target price on shares of Enovix from $18.00 to $12.00 and set an overweight rating on the stock in a report on Friday, April 26th. Craig Hallum decreased their target price on shares of Enovix from $20.00 to $15.00 and set a buy rating on the stock in a report on Thursday, May 2nd. Finally, B. Riley raised shares of Enovix to a strong-buy rating in a research note on Tuesday, June 25th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Enovix presently has an average rating of Buy and a consensus price target of $19.57.
View Our Latest Report on ENVX
Enovix Stock Performance
Enovix (NASDAQ:ENVX – Get Free Report) last posted its earnings results on Wednesday, May 1st. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The firm had revenue of $5.27 million during the quarter, compared to analyst estimates of $4.16 million. Enovix had a negative net margin of 1,434.34% and a negative return on equity of 84.28%. As a group, sell-side analysts expect that Enovix will post -1.14 EPS for the current fiscal year.
Insider Activity
In related news, Director Gregory Reichow sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $12.14, for a total transaction of $91,050.00. Following the sale, the director now directly owns 8,129 shares of the company’s stock, valued at approximately $98,686.06. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 17.30% of the company’s stock.
Institutional Investors Weigh In On Enovix
A number of hedge funds have recently added to or reduced their stakes in the business. Wealth Effects LLC lifted its holdings in Enovix by 55.6% during the 2nd quarter. Wealth Effects LLC now owns 229,001 shares of the company’s stock worth $3,540,000 after buying an additional 81,801 shares in the last quarter. Rhumbline Advisers lifted its holdings in Enovix by 13.7% during the 2nd quarter. Rhumbline Advisers now owns 221,966 shares of the company’s stock worth $3,432,000 after buying an additional 26,724 shares in the last quarter. Natixis Advisors LLC acquired a new stake in Enovix during the 2nd quarter worth approximately $247,000. Cutter & CO Brokerage Inc. lifted its holdings in Enovix by 6.5% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 44,268 shares of the company’s stock worth $684,000 after buying an additional 2,695 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in Enovix by 45.2% during the 2nd quarter. Commonwealth Equity Services LLC now owns 69,414 shares of the company’s stock worth $1,073,000 after buying an additional 21,620 shares in the last quarter. 50.92% of the stock is currently owned by institutional investors and hedge funds.
Enovix Company Profile
Enovix Corporation designs, develops, and manufactures lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.
Read More
- Five stocks we like better than Enovix
- Quiet Period Expirations Explained
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- 3 Warren Buffett Stocks to Buy Now
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Invest in Insurance Companies: A GuideĀ
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Enovix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovix and related companies with MarketBeat.com's FREE daily email newsletter.